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Abstract: In this study, we aim to explore the effects on lipids of integrase strand transfer inhibitors
(INSTIs) in naïve and switch randomised controlled trials, and compare them with protease inhibitors
(PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). We reviewed phase 3/4 ran-
domised clinical trials in the Cochrane and PubMed databases that compare an INSTI with a boosted
PI, an NNRTI, or another INSTI plus one or two nucleoside/nucleotide reverse transcriptase in-
hibitors (NtRTIs) in naïve patients and switching strategies in HIV-infected patients. We reported the
baseline plasma concentration of total cholesterol (TC), low and high-density lipoprotein cholesterol
(LDL-c, HDL-c), triglycerides (TG), and the TC/HDL-c ratio, as well as the change at weeks 48 and
96, when available. In naïve HIV-infected patients, raltegravir (RAL) and dolutegravir (DTG) have
a more favourable lipid profile compared with NNRTI and boosted PI. Elvitegravir (EVG/c) has a
superior lipid profile compared with efavirenz and is similar to that observed with ritonavir-boosted
atazanavir except in TG, which increases less with EVG/c. In naïve patients, RAL, DTG, and bicte-
gravir (BIC) produce a similar, slight increase in lipids. In switching trials, the regimen change based
on a boosted PI or efavirenz to RAL, DTG, or BIC is associated with clinically significant decreases in
lipids that are minor when the change is executed on EVG/c. No changes were observed in lipids
by switching trials between INSTIs. In summary, RAL, DTG, and BIC have superior lipid profiles
compared with boosted-PI, efavirenz, and EVG/c, in studies conducted in naïve participants, and
they are associated with a clinically significant decrease in lipoproteins by switching studies.
Keywords: integrase strand transfer inhibitors; antiretroviral therapies; HIV; lipid profile; ran-
domised controlled trials
1. Introduction
Since the introduction of combined antiretroviral therapy (ART) in 1996, there has been
a decrease in the global mortality of people living with human immunodeficiency virus
type 1 (HIV-1; PLWH), mainly concerning deaths related to acquired immunodeficiency
syndrome (AIDS). However, the proportion of deaths from non-AIDS-related disorders,
such as cardiovascular (CV), non-AIDS cancer, and liver diseases, has increased [1]. The
risk of myocardial infarction is one and a half- to two-fold greater in PLWH compared with
the general population, and is similar to diabetes mellitus, hypertension, or smoking [2].
The increased CV risk in PLWH is due to the addition of several factors, such as the effects
of HIV through inflammation and immune activation that are not completely reverted
by combined ART, the higher frequency of traditional CV risk factors in PLWH, and the
deleterious effects of some antiretroviral drugs on lipid and glucose metabolism [3]. Several
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factors may interact, favouring the presence of lipid disorders in PLWH, among them, HIV,
lifestyle factors (including diet and exercise), genetic factors, and ART [4].
Non-treated chronic HIV infection, as well as other chronic infections and inflam-
mation conditions, is associated with an atherogenic lipid phenotype. This phenotype is
characterized by changes in lipid concentrations, including decreased levels of high-density
lipoprotein cholesterol (HDL-c), total cholesterol (TC), and increased levels of triglycerides
(TG), as well as modifications in lipid composition and function [5–8]. The initiation of
combined ART has been associated with lipid changes, which can be considered a return
to a “healthy” state [5,8].
ART has evolved rapidly since 1986, when the first active drug against HIV, zidovu-
dine, a nucleoside reverse transcriptase inhibitor (NRTI), became available. Since then, new
drugs from the same family and new families of drugs have been incorporated into the
HIV therapeutic arsenal (Table 1). In 2007, the integrase strand transfer inhibitor (INSTI)
family joined the arsenal of HIV treatment. Raltegravir (RAL) was the first to be approved,
followed by cobicistat-boosted elvitegravir (EVG/c), dolutegravir (DTG), bictegravir (BIC),
and recently, cabotegravir. INSTIs have proven effective and safe, with a good lipid profile,
for treatment-naïve patients and switching strategies in HIV-1-infected patients, which is
why DTG and BIC are guideline-preferred regimens for the initial treatment of PLWH and
are largely used in switching strategies to improve toxicities [9,10].
Table 1. Antiretroviral drugs approved in Spain up to May 2021.
Nucleoside/Nucleotide Reverse
































* Drugs not further used. r: ritonavir; c cobicistat.
Combined ART consists of a backbone of two nucleoside/nucleotide reverse tran-
scriptase inhibitors (NtRTIs) and a third drug that may be an INSTI, a boosted protease
inhibitor (PI), or a non-nucleoside reverse transcriptase inhibitor (NNRTI) [9,10]. Lipid
disorders associated with ART differ significantly depending on the family and within the
same family. Old PIs, NRTIs, and some NNRTIs are the agents most frequently related to
increases in TG, TC, and low-density lipoprotein cholesterol (LDL-c). The management
of lipid disorders has been an important issue in the treatment of PLWH, and is based
on guidelines used in the general population, as well as the possibility of switching any
component of the ART combination to another with a superior lipid profile [11]. Current
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guidelines consider switching a boosted PI or efavirenz (EFV)-based regimen to INSTI in
patients with dyslipidemia or CV events [9,10]. The objective of this review is to explore
the effects on lipids of INSTI compared with PIs and NNRTIs and examine whether the
lipid profile differs among INSTIs in naïve and switch randomised controlled trials (RCTs).
2. Materials and Methods
In the Cochrane and PubMed databases, we reviewed RCTs that compared a regimen
including an INSTI with a regimen including another INSTI, a boosted PI, or an NNRTI,
plus one or two NtRTIs, recommended in past and current guidelines [9,10]. From the
selected RCTs, we included phase 3/4 RCTs conducted in naïve HIV-infected patients and
switch trials where the PI, NNRTI, or INSTI of a combined ART regimen was changed to
an INSTI in virologically suppressed HIV-infected patients. We excluded RCTs conducted
in special populations, such as pregnant women, children, or those using drug doses other
than those approved [9,10]. We also excluded trials without data on plasma lipids.
We reported the baseline TC, LDL-c, HDL-c, TG, and the TC/HDL-c or HDL-c/TC
ratio in each arm, when available. We also reported the mean (standard deviation [SD])
or median (interquartile range [IQR]) change from baseline to week 48 for each variable.
When available, we described the changes at week 96 to assess the long-term effects of
INSTIs. Data are presented in mg/dL. Since the study design, participants, interventions,
and reported outcome measures vary markedly, we focused on describing the studies and
their results rather than meta-analysing them.
3. Results and Discussion
3.1. Comparison of INSTIs with Other ART Families in Treatment-Naïve Patients
3.1.1. Raltegravir
In the STARTMRK trial, RAL was compared with EFV in combination with tenofovir
disoproxil fumarate (TDF) and emtricitabine (FTC). At week 48, there was a greater increase
in the EFV arm than in the RAL arm in terms of TC, LDL-c, HDL-c, and TG (p ≤ 0.001 for
all comparisons except for LDL-c, where p = 0.002), whereas the HDL-c/TC ratio did not
change in any arm [12]. At week 96, the mean change from baseline decreased in both
arms compared with week 48, but persisted at a significantly higher level in the EFV arm
compared with the RAL arm in terms of TC, LDL-c, HDL-c, and TG (p < 0.001 for each
comparison). The HDL-c/TC ratio remained unchanged in both arms. Lipid-lowering
therapy was used in 7% of subjects with the RAL arm and 9% of subjects with the EFV arm
at some point through week 96 (Table 2) [13].
The AIDS Clinical Trials Group (ACTG) A5257 trial compared RAL, ritonavir-boosted
darunavir (DRV/r), and atazanavir (ATZ/r) combined with TDF and FTC. At week 48,
there was a greater increase in DRV/r and ATZ/r compared with the RAL arm in TC,
LDL-c, and TG (p ≤ 0.001 for all comparisons). At week 96, similar mean changes from
baseline were found in the three arms in terms of TC, LDL-c, and TG (all p ≤ 0.001). HDL-c
increased modestly, with no significant differences between the three arms. From baseline
to week 96, the percentage of participants who received lipid-lowering therapy increased
from 6% to 14% in the DRV/r arm, 5% to 11% in the ATZ/r arm, and 6% to 9% in the RAL
arm [14], respectively (Table 2).
3.1.2. Elvitegravir
The co-formulated EVG/c, TDF, and FTC was compared with the co-formulated EFV,
TDF, and FTC. At week 48, median concentrations of TC, LDL-c, and HDL-c increased
less in the EVG/c arm (9.6, 10, and 5, respectively) than in the EFV arm (17.4, 16.8, and
7.7, respectively; p ≤ 0.001). Changes in the TC/HDL-c ratio and TG were similar in both
groups [15].
The co-formulated EVG/c, TDF, and FTC were also compared with ATZ/r plus TDF
and FTC. At week 48, the median (IQR) increases in TC, LDL-c, and HDL-c did not differ
between arms; these increases were 10 (−6.29), 10.8 (−4.25), and 5.8 (0.12), respectively,
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in the EVG/c arm and 8 (−12.30), 10.4 (−8.27), and 5 (2.11) for the same variables in
the ATZ/r arm. TG increased more in the ATZ/r arm compared with the EVG/c arm
(23 (−11.59) vs. 8 (−19.37); p = 0.006] [16]. At week 96, there was a significant increase
(p = 0.046) in median TC in the EVG/c arm (14 (−3.31)) compared with that of the ATZ/r
arm (8 (−12.30)). By contrast, TG had a greater increase in the ATZ/r arm compared
with the EVG/c arm (16 (−13.52) vs. 5 (−22.37); p = 0.012). There were no significant
changes from baseline through week 96 for LDL-c, HDL-c, and the TC/HDL-c ratio in
either treatment arm [17].
The WAVES trial compared the co-formulated EVG/c, TDF, and FTC with ATZ/r, TDF,
and FTC in women. The median (IQR) changes at week 48 in terms of TC, LDL-c, HDL-c,
and TG were slight and similar between groups. The levels were 7 (−7.25), 0 (−13.14),
4 (−3.11), and 5 (−16.27) in the EVG/c arm, and 2 (−14.20), −2 (−15.11), 3 (−3.10), and
8 (−18.35) in the ATZ/r arm. The median change in TC/HDL-c ratio was −0.1 in both
groups [18].
3.1.3. Dolutegravir
The SINGLE trial compared DTG, abacavir (ABC), and lamivudine (3TC) with the
co-formulated EFV, TDF, and FTC. At week 48 in the EFV arm, there was a greater increase
in mean TC (p = 0.005) and LDL-c (p = 0.032); TG and HDL-c showed a similar increase in
both arms. The median change in the TC/HDL-c ratio was −0.1 in both arms [19,20]. Small
increases in lipid variables were observed in both arms from weeks 48 to 96 (Table 2) [21].
The FLAMINGO trial compared DTG and DRV/r combined with TDF and FTC (67%)
or ABC and 3TC (33%). At week 48, the mean increase in TC, LDL-c, and TG was greater
in the DRV/r arm compared with the DTG arm. The mean increase in HDL-c was small,
slight and comparable between the two arms, whereas the TC/HDL-c ratio increased only
in the DRV/r arm (Table 2) [20,22].
A fixed-dose combination of DTG, ABC, and 3TC was compared with ATZ/r plus
TDF, and FTC in the ARIA trial for women. There were no significant differences between
the two treatment arms in the mean change from baseline in TC/HDL-c ratio and TG [23].
The ADVANCE trial compared DTG and FTC plus either tenofovir alafenamide (TAF)
or TDF against the co-formulated EFV, TDF, and FTC. The study was conducted in South
Africa. At week 48, small changes in both regimens containing DTG were favourable to the
TDF-containing regimen (p < 0.05 for all variables, except HDL-c at p = 0.05). In the EFV
arm at week 48, there was a greater increase in TC and HDL-c compared with the DTG-
TAF-based regimen (p < 0.05) and in all lipid variables compared with the DTG-TDF-based
regimen (p < 0.001, except TG, at p = 0.0058) (Table 2) [24].
3.1.4. Summary of Studies Comparing INSTI-Based Regimens with Other ART Families in
Treatment-Naïve Patients
RAL and DTG were associated with a lower increase in TC, LDL-c, and TG compared
with efavirenz and PI/r-based regimens. By contrast, HDL-c increased more in EFV-based
regimens. INSTI-based regimens were associated with no increase in the TC/HDL-c ratio.
In the STARTMRK trial, the high baseline plasma lipid concentrations were notable, as well
as their increase at week 48 in both the RAL and EFV arms. Elvitegravir, the only cobicistat-
boosted INSTI, was associated with an intermediate effect on lipid plasma concentrations
between the other INSTIs and PI/r or EFV. Cobicistat is a CYP3A4 inhibitor that shows
a lower potential for worsening lipid metabolism compared with ritonavir other in vitro
studies [25]. However, when combined with EVG, it has a slightly worse metabolic profile
compared with non-enhancer INSTIs.
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Table 2. Comparison of INSTIs with other ART families in treatment-naïve patients.
Trial,
Year [Ref]
Design of the Study
Treatment Arm











n = 281;37.6; 81%
Baseline 1 342 (75.7) 208.1 (67.6) 82.2 (27) 613.3 (361.1) 0.25 (0.08) a
Week 48 2 21.2 (62.5) 12.7 (52.9) 8.9 (18.1) −14.2 (400) −0.02 (0.06) a
Week 96 3 10 7 3 −4 7%
Efavirenz, TDF, FTC,
n = 282; 36.9; 82%
Baseline 1 333.9 (82.2) 198.5 (65.6) 81.1 (23.9) 669.9 (606.2) 0.24 (0.08) a
−0.01 (0.08) aWeek 48 2 70.3 (72.2) * 34.4 (62.2) * 21.6 (23.5) * 184.1 (633.6) *





n = 600; 37; 76%
Baseline 4 158.3 (155,161) 94.9 (92,97) 39.5 (38,41) 123.4 (117,130) 6%
Week 48 5 159.5 (156,162) [1.2] 92.2(90,95) [−2.9] 44.5 (43,46) 115.3 (109,122) [−7.1]
Week 96 5 163.4 (160,166) [5.2] 92 (90,94) [0.1] 45.4 (44,47) 116.3 (110,123) [−7.1] 9%
DRV/r, TDF, FTC,
n = 595; 37.5; 76%
Baseline 4 157 (154,160) 93 (90,95) 40.4 (39,41) 124.3 (117,131) 6%
Week 48 5 172 (169,176) [15.3] * 99.1 (96,102) [6.1] * 46 (45,47) 137.3 (130,145) [16.8] *
Week 96 5 172 (169,176) [15.4] * 99.9 (97,103) [5.1] * 46 (44,47) 141.1 (131,151) [16.8] * 14%
ATZ/r, TDF, FTC,
n = 602; 37.6; 76%
Baseline 4 156.7 (154,159) 93.7 (91, 96) 38.8 (38,40) 123.8 (117,130) 5%
Week 48 5 169.8 (166,173) [13.1] * 97.4 (94,100) [3.7] * 45.1 (44,46) 139.7 (132,147) [17.1] * 11%



































DTG, TDF, FTC or ABC, 3TC













DRV/r, TDF, FTC or ABC, 3TC




















































Only studies showing baseline data are shown. * p-value < 0.05 for comparisons between treatment arms. † p-value < 0.05 for the comparison between DTG, TAF, FTC, and DTG, TDF, FTC. †† p-value < 0.05 for
the comparison between EFV and DTG containing regimens. a HDL-c/TC ratio. Superindex numbers indicate the statistical parameters to express data: 1 Mean (standard deviation); 2 Mean change (standard
deviation); 3 Mean change; 4 Mean absolute value (95% confidence interval); 5 Mean absolute value (95% confidence interval) [mean change]; 6 Median (interquartile range); 7 Median change (interquartile range).
Abbreviations: ABC, abacavir; ATZ/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; DTG, dolutegravir; FTC, emtricitabine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate;
3TC lamivudine.
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3.2. Comparison of Different INSTIs Strategies in Treatment-Naïve Patients
3.2.1. Elvitegravir
Elvitegravir/c plus either TAF and FTC or TDF and FTC were compared. At week
48, the median increase in TC, LDL-c, HDL-c, and TG was greater—almost double—in the
TAF-containing regimen (p < 0.001 for all variables except TG, p = 0.027), whereas a slight,
similar increase (p = 0.84) was observed in both arms in the TC/HDL-c ratio. Thirty-one
(3.6%) participants in the TAF-containing arm and twenty-five (2.9%) in the TDF-containing
arm started lipid-lowering therapy (p = 0.42) (Table 3) [26].
3.2.2. Dolutegravir and Bictegravir
DTG was compared with BIC, both combined with TAF and FTC, in the GS-US-380-
1490 study. There were no differences in the median, mostly increasing changes of lipid
parameters from baseline at weeks 48 and 96 in both arms. Lipid-lowering therapy was
initiated at weeks 48 and 96 in 2% and 3% of cases in the BIC arm, and 2% and 4% in the
DTG arm, respectively (Table 3) [27,28].
DTG combined with ABC and 3TC was compared with BIC combined with TAF and
FTC in the GS-US-380-1489 trial. There were no differences in the median changes of lipid
variables from baseline at week 48, except a small but statistically significant decrease of
TC/HDL-c ratio in the DTG arm (p = 0.0130). During the study, initiations of lipid-lowering
therapy were 2.5% and 2.9% in the BIC and DTG arms, respectively. At week 96, in the BIC
arm, small but significantly larger increases were found in TC (p = 0.002), LDL-c (p < 0.001),
and the TC/HDL-c ratio (p = 0.003) (Table 3) [29,30].
3.2.3. Dolutegravir and Raltegravir
DTG and RAL combined with co-formulated ABC and 3TC (40–41%) or TDF and FTC
(59–60%) were compared in the SPRING-2 trial. Small and nonsignificant changes over
time in the fasting lipid profile were noted in the arms (Table 3) [20,31].
3.2.4. Summary of Studies Comparing INSTs in Treatment-Naïve Patients
The initiation of RAL, DTG, or BIC was associated with similar and slight increases in
plasma concentrations of TC, LDL-c, and HDL-c when the background of NRTI included
TAF or ABC. This increase was higher than expected for the intraindividual long-term
biological variation, which was established in 6% for TC, 7.8% for LDL-c, 19.9% for TG,
and 7.3% for HDL-c [32]. These increases may be considered a return of a healthier state in
terms of lipids, as previously described in observational studies, and they may be related
to decreases in inflammation and immune activation mediated by virological suppres-
sion [5,8]. However, when RAL and DTG (no data are available for BIC) were combined
with TDF, no changes or even a tendency toward reducing lipid plasma concentrations
were found in the trials. These data confirm the intrinsic lipid-lowering effect of TDF
shown in the TULIP trial [33]. It is noteworthy that the increases observed with RAL, DTG,
and BIC were similar to those observed with DRV/r and ATZ/r combined with TDF in
the ACTG 5257, reinforcing the hypolipidemic effects of TDF even when it is associated
with a PI/r. However, the requirement of lipid-lowering therapy with the three INSTIs was
exceedingly low, suggesting the low clinical relevance of the mentioned increases.
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Table 3. Comparison of different INSTIs in treatment-naïve patients.
Trial,
Year [Ref]
Design of the Study
Treatment
n (Participants); Age; % Men Study Period Total Cholesterol LDL-c HDL-c Triglycerides TC/HDL-c





































n = 325; 34; 89%
Baseline 3 161 (138,186) 99 (82,124) 43 (35,52) 95 (70,131) 3.7 (3.1,4.5)
Week 48 4 15 (1,31) 12 (−3,25) 5 (−1,12) 7 (−14,35) −0.1 (−0.6,0.4) 6 (2%)
Week 96 4 16 (−2,34) 16 (0,32) 5 (−1,12) 6 (−17,32) −0.1 (−0.6,0.5) 12 (4%)
BIC, TAF, FTC
n = 320; 33; 88%
Baseline 3 156 (136,182) 98 (81,120) 43 (35,52) 97 (72,134) 3.7 (3,4.5)
Week 48 4 12 (−3,30) 9 (−6,25) 5 (0,11) 3 (−21,31) −0.1 (−0.5,0.3) 5 (2%)






n = 315; 32; 90%
Baseline 3 162 (138,186) 101 (84,126) 42 (35,51) 96 (66,138) 3.7 (3,4.6)
Week 48 4 11 (−6,28) 4 (−9,18) 5 (0,11) 3 (−25,27) −0.2 (−0.7,0.2) 9 (2.9%)
Week 96 4 8 (−7,36) 5 (−5,24) 5 (−1,12) 6 (−21,30) −0.2 (−0.7,0.3)
BIC, TAF, FTC
n = 314; 31; 91%
Baseline 3 159 (133,181) 101 (83,123) 42 (34,51) 93 (67,132) 3.7 (3,4.7)
Week 48 4 13 (−3,31) 7 (−5,21) 5 (−2,11) 5 (−20,37) −0.1 (−0.5,0.4) * 8 (2.5%)




DTG, TDF, FTC or ABC, 3TC;













RAL, TDF, FTC or ABC, 3TC;













Only studies with baseline data are shown. * p-value < 0.05 for comparisons between treatment arms. Superindex numbers indicate the statistical parameters to express data: 1 Median; 2 Median change; 3
Median (interquartile range); 4 Median change (interquartile range) 5 Mean (standard deviation); 6 Mean change (standard deviation). Abbreviations: ABC, abacavir; BIC, bictegravir; DTG, dolutegravir; EVG/c,
cobicistat-booster elvitegravir; FTC, emtricitabine; RAL, raltegravir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; 3TC lamivudine.
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3.3. Switch Studies from a PI or NNRTI-Based Regimen to a Regimen That Includes an INSTI in
Virologically Suppressed HIV-Infected Patients
Dyslipidemia may be an adverse event following some ART drugs, mainly ritonavir-
or cobicistat-boosted regimens or EFV. The switch to an INSTI may be an option to improve
lipid disturbances. We reviewed RCTs that included participants who were virologically
suppressed for more than 3 months on a stable combined ART regimen.
3.3.1. Raltegravir
In the SPIRAL study, patients treated with PI/r (mainly lopinavir/r (44%) and ATZ/r
(35%) were randomised to switch to RAL or continue on a PI/r-based regimen while
maintaining the same NtRTIs. At week 48, significant reductions in TC, LDL-c, HDL-c, TG,
and the TC/HDL-c ratio in the RAL arm were compared with predominant increases in the
PI/r arm (p < 0.001 for all comparisons except TC/HDL-c, where p < 0.05). The percentage
of participants on lipid-lowering therapy at week 48 was double that of the RAL (12%) arm
in the PI/r arm (24%) (Table 4) [34].





















n = 139; 44; 81%
Baseline 1 198 (171,226) 121(97,141) 44 (35,54) 168 (117,270) 27 (19%)
Week 48 2 −22.2 (−11.2%) −7.9 (−6.5%) −1.4 (−3.2%) −37.1 (−22.1%) −4.85% 16 (12%)
PI/r;
n = 134; 45; 72%
Baseline 1 198(171,223) 122 (97,147) 43 (37,51) 174 (114,236) 28 (21%)





n = 293; 41; 85%
Baseline 3 186.9 (39) 120.8 (34.4) 50.9 (15.4) 153.1 (154.9) 3.9 (1.24)
Week 48 4 −4.4 (62.8) −1.2 (22.8) 1.2 (8.5) −29.2 (143.4) −0.1 (0.8)
PI/r, TDF, FTC
n = 140; 40; 86%
Baseline 3 189.9 (38.2) 123.9 (33.6) 50.2 (12.7) 145.1 (79.6) 4 (1.12)






n = 291; 43; 92%
Baseline 3 191.1 (35.5) 120.8 (30.9 54 (14.3) 140.7 (116.8) 3.7 (1.1)
Week 48 4 −6.9 (31.3) −3.9 (26.6) −3.1 (9.3) −4.4 (81.4) 0.1 (0.8)
NNRTI, TDF, FTC
n = 143; 39; 94%
Baseline 3 188 (35.5) 118.1 (32) 52.9 (15.1) 141.6 (107.9) 3.8 (1.3)






n = 159; 36
Baseline 1 171 (148,203) 105 (89,133) 50 (43,61) 105 (80,141) 3.3 (2.8,4.1) 2 (1%)
Week 48 5 27 (7,46) 16 (1,34) 5 (−1,12) 3 (−20,33) 0.1 (−0.1,0.5)
ATZ/r, TDF, FTC
n = 53; 36
Baseline 1 180 (254,201) 115 (95,133) 56 (44,64) 105 (80,136) 3.2 (2.7,4.1) 0





n = 205; 54; 88.3%
Baseline 1 201 (174,223) 120 (97,143) 46 (39,58) 142 (106,204) 4.2 (3.4,5.4)
Week 48 2 −17.5 (8.7%) −9.2 (7.7%) 0.5 (1.1%) −26.1 (18.4%) −0.3 (7%)
Week 96 2 −15.7 (7.8%) −8.3 (6.9%) 1.3 (2.9%) −22.2 (15.6%) −0.3 (6.4%)
DTG-deferred
n = 210; 53; 90%
Baseline 1 197 (174,216) 120 (97,139) 46 (39,58) 142 (106,195) 4.1 (3.4,5.2)
Week 48 2 1.4 (0.7%) * 2.4 (2%) * 1.1 (2.5%) 5.9 (4.2) * 0.02 (0.4%)





n = 285; 48; 84%
Baseline 1 188 (163,215) 121 (101,148) 47 (39,55) 122 (83,176) 4 (3.3,4.9) 8 (3%)
Week 48 5 1 (−17,20) 0 (−16,15) 3 (−3,7) −6 (−42,22) −0.2 (−0.6,0.3)
BIC, TAF, FTC
(from ABC/3TC);
n = 47; no data
Baseline 1 199 (178,223) 130 (113,157) 50 (40,56) 128 (87,170) 4.1 (3.4,4.9)
Week 48 5 −11 (−31,2) * −7 (−31,0) * 1 (−4,5) −31 (−51,−1) * −0.4 (−0.7,0) *
PI/r or PI/c and TDF,
FTC or ABC, 3TC;
n = 287; 47; 82%
Baseline 1 183 (160,214) 118 (98,143) 46 (39,57) 121 (87,163) 3.8 (3.1,4.9) 10 (3%)
Week 48 5 5 (−12,18) 3 (−14,18) 1 (−4,7) 4 (−29,38) * 0 (−0.5,0.4) *
Only studies with baseline data are shown. * p-value < 0.05 for comparisons between treatment arms. Superindex numbers indicate
the statistical parameters to express data: 1 Median (interquartile range); 2 Median change [percentage of change]; 3 Mean (standard
deviation); 4 Mean change (standard deviation); 5 Median change (interquartile range). Abbreviations: ABC, abacavir; ATZ/r, ritonavir-
boosted atazanavir; BIC, bictegravir; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; EVG/c, cobicistat-booster elvitegravir;
FTC, emtricitabine; PI/c, cobicistat-boosted protease inhibitor; PI/r, ritonavir-boosted protease inhibitor; RAL, raltegravir; TAF, tenofovir
alafenamide; TDF, tenofovir disoproxil fumarate; 3TC lamivudine.
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3.3.2. Elvitegravir
In the STRATEGY-PI trial, patients on a PI/r-based regimen (ATZ/r (41%), DRV/r
(39.9%), or lopinavir/r (16.6%) plus TDF and FTC were randomised to switch to co-
formulated EVG/c, TDF, and FTC or continue on the PI/r-based regimen. At week 48,
in the overall group, only TG plasma levels decreased significantly in the EVG/c arm
compared with the PI/r arm (p = 0.001). However, lipid changes differed depending on the
baseline PI/r. In patients that switched from ATZ/r, a mean (SD) change in the level of TG
of −31.9 (207.1) was observed in patients who switched to EVG/c compared with those
who continued on ATZ/r (5.3 (80.5); p = 0.014). By contrast, in patients who switched from
DRV/r, there was a significant increase in HDL-c (1.9 (9.3)) and a decrease in TC/HDL-c
ratio (−0.2 (0.78)) for those who changed to EVG/c compared with those who continued
on DRV/r (−1.2 (8.1); p = 0.03 and 0 (0.62); p = 0.029, respectively). Finally, in participants
who switched from lopinavir/r, there was a significant decrease in TC of 23.9 (27), TG of
59.3 (55.7), and HDL-c of 1.9 (8.9) in those who changed to EVG/c compared with those
who continued on lopinavir/r (TC 1.2 (22.4); p = 0.002, TG-0.9 (78.8); p = 0.003 and HDL
6.2 (9.3); p = 0.016) (Table 4) [35].
In the STRATEGY-NNRTI trial, patients on an NNRTI-based regimen (EFV (77.9%),
nevirapine (17%), or rilpivirine (4.4%)) plus TDF and FTC were randomised to switch
to co-formulated EVG/c, TDF, and FTC or to continue in the NNRTI-based regimen. At
week 48, in the overall group, only HDL-c plasma levels decreased significantly in the
EVG/c arm compared with those who continued in the NNRTI-based regimen (p = 0.001).
Lipid changes differed depending on the baseline NNRTI. In patients switching from EFV
to the EVG/c-based regimen, there were mean decreases in TC of 6.9 (31.3), LDL-c of
3.9 (26.6), and HDL-c of 3.1 (9.3) compared with those who continued on EFV (TC 1.2 (22.4),
p = 0.01, LDL-c 3.9 (21.2), p = 0.001 and HDL-c 0 (9.3), p = 0.008). By contrast, in participants
switching from nevirapine or rilpivirine to EVG/c, there were significant increases in LDL-c
of 8.1 (25.9) and the TC/HDL-c ratio of 0.4 (1.42) compared with those who continued
with nevirapine or rilpivirine (LDL-c −3.9 (23.9), p = 0.018 and TC/HDL-c ratio −0.1 (0.62).
p = 0.026) (Table 4) [36].
Participants remaining in treatment with ATZ/r plus TDF and FTC from the WAVES
study [18] were randomised to change to the co-formulated EVG/c, TAF, and FTC or to
continue with ATZ/r, TDF and FTC. At week 48, the median TC, LDL-c, and HDL-c values
increased in EVG/c and remained stable in the ATZ/r arm (p-values of the comparison
<0.001, 0.002, and 0.009, respectively). No differences were observed for TG or the TC/HDL
ratio between the arms. Two participants started lipid-lowering therapy in the EVG/c arm,
whereas none underwent lipid-lowering therapy in the ATZ/r arm (Table 4) [37].
3.3.3. Dolutegravir
In the NEAT022 study, participants on a stable triple therapy regimen consisting of a
PI/r (DRV/r (51.2%), ATZ/r (36.5%), lopinavir/r (8.7%)) plus two NtRTIs, aged ≥50 years
or ≥18 years with a Framingham cardiovascular disease (CVD) 10-year risk score >10%,
were randomised to switch to DTG (DTG-immediate) or remain on PI/r, while maintaining
the same two NtRTIs. At week 48, patients remaining on the PI/r were switched to DTG
(DTG-deferred) and followed up to 96 weeks. At week 48, median TC, LDL-c, TG, and
TC/HDL-c ratio decreased in the DTG-immediate arm compared with the DTG-deferred
arm (p < 0.001 for all comparisons). No changes were observed in HDL-c in any arm. At
week 96, TC, LDL-c, TG, and the TC/HDL-c ratio decreased from baseline at similar levels
in both arms (p > 0.05) (Table 4) [38].
3.3.4. Bictegravir
In the present trial, participants on a stable triple therapy regimen consisting of a
cobicistat or ritonavir-PI regimen (DRV (55.1%) and ATZ (44.8%)) plus either TDF and FTC
(84%) or ABC and 3TC (15%) were randomised to switch to co-formulated BIC, TAF, and
FTC or to remain on their baseline boosted-PI regimen. At week 48, TG and the TC/HDL-
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c ratio decreased in the BIC arm compared with the overall boosted-PI arm (p = 0.002
and p = 0.033, respectively). However, lipid changes differed depending on the baseline
background of NtRTI. Small and nonsignificant changes were observed in participants who
switched to the BIC arm from a boosted-PI regimen containing TDF and FTC. However, in
participants switching from an ABC and 3TC regimen, the switch to BIC, TAF, and FTC was
associated with significant decreases in TC (p = 0.0002), LDL-c (p = 0.001), TG (p = 0.0001),
and the TC/HDL-c ratio (p = 0.012) than continuing with the boosted-PI (Table 4) [39].
3.3.5. Summary of Switching Studies from a PI or NNRTI-Based Regimen to a Regimen
That Includes an INSTI in Virologically Suppressed HIV-Infected Patients
The switch from a PI/r-based regimen to a RAL- or DTG-based regimen while main-
taining the same background NtRTI was associated with significant decreases in TC, LDL-c,
TG, and the TC/HDL-c ratio. By contrast, the switch from a PI/r-based regimen to EVG/c,
both in combination with TDF and FTC, was associated with a significant decrease only
in TG. The switch from an NNRTI to EVG/c, maintaining TDF plus FTC, was associated
with changes in lipids that differed depending on the baseline NNRTI, with beneficial
effects only when it was an EFV. Finally, the effect on lipids by switching from a PI-based
regimen to the co-formulated BIC, TAF, and FTC depended on whether participants were
undergoing regimens containing TDF or ABC at baseline. When the baseline regimen
contained TDF, the switch to BIC resulted in no change in any fasting lipid parameter at
week 48, indicating that the effect of switching away from TDF was balanced by switching
from PI/r to BIC. By contrast, in participants on regimens containing ABC plus 3TC at
baseline, the switch to BIC was associated with significant improvements in TC, LDL-c,
TG, and the TC/HDL ratio, suggesting a neutral lipid profile for both BIC and TAF.
3.4. Switch Studies on INSTIs in Virologically Suppressed HIV-Infected Patients
The present study included women undergoing treatment with EVG/c plus TDF and
FTC (42%) or TAF and FTC (53%); 5% underwent treatment with ATV/r plus TDF and
FTC. Patients were randomised to switch to the co-formulated BIC plus TAF and FTC or to
continue on the baseline regimen. Overall, at week 48, changes from baseline were similar
and small in both arms for TC, LDL-c, HDL-c, and TC/HDL-c. Only the median TG change
at week 48 differed between arms, favouring the BIC arm (p < 0.001). Similar percentages
of participants started a lipid-lowering therapy in both arms, with 2% in BIC and 4% in
those who continued with the baseline regimen (Table 5) [40].
Table 5. Switch studies between INSTIs in virologically suppressed HIV-infected patients.
Trial,
Year [Ref]














FTC or TAF, FTC;
n = 236; 40; no data
Baseline 1 193 (167,225) 122 (100,149) 56 (46,68) 99 (75,137) 3.4 (2.8,4.1)
Week 48 2 −1 (−17,16) −1 (−14,13) −1 (−6,5) 4 (−15,28) 0 (−0.3,0.3) 4%
BIC, TAF, FTC
n = 234; 39; no data
Baseline 1 196 (171,224) 120 (101,151) 56 (47,69) 105 (78,151) 3.4 (2.9,4.1)




n = 281; 45; 90%
Baseline 1 186 (162,213) 118 (99,141) 48 (41,59) 111 (78,156) 3.8 (3,4.7) 1%
Week 48 2 2 (−17,18) 2 (−14,14) 0 (−4,6) 3 (−23,30) 0 (−0.5,0.4)
BIC, TAF, FTC
n = 282; 47; 88%
Baseline 1 182 (162,203) 113 (95,133) 49 (40,59) 111 (76,161) 3.7 (3,4.5) 4%




n = 281; 50; 85%
Baseline 1 179 (156,209) 107 (91,137) 44 (38,55) 130 (83,179) 3.9 (3.3,4.8) 3%
Week 48 2 −1 (−18,17) 4 (−11,17) 1 (−4,5) 0 (−26,30) 0 (−0.4,0.4)
BIC, TAF, FTC
n = 284; 51; 86%
Baseline 1 179 (150,208) 107 (82,133) 46 (39,58) 117 (83,159) 3.7 (3.1,4.6) 5%
Week 48 2 −1 (−20,15) 3 (−14,19) 0 (−4,4) 1 (−30,30) −0.1 (−0.4,0.4)
Only studies with baseline data are shown. * p-value < 0.05 for comparisons between treatment arms. Superindex numbers indicate the
statistical parameters to express data:1 Median (interquartile range); 2 Median change (interquartile range). Abbreviations: ABC, abacavir;
BIC, bictegravir; DTG, dolutegravir; EVG/c, cobicistat-booster elvitegravir; FTC, emtricitabine; TAF, tenofovir alafenamide; TDF, tenofovir
disoproxil fumarate; 3TC lamivudine.
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Two RCTs assessed the switch of a regimen based on DTG to a regimen based on
BIC [41,42]. In the first study, participants on treatment with DTG, ABC, and 3TC were
randomised to switch to co-formulated BIC, TAF, and FTC or remain on the baseline
regimen. At week 48, the median change from baseline in TC, LDL-c, HDL-c, and the
TC/HDL-c ratio were small and similar between groups. The median TG change at week
48 favoured the BIC arm (p = 0.028). One per cent of patients started lipid-lowering therapy
in the BIC arm, and 4% started in the DTG arm (p = 0.033) [41]. In the second study,
participants underwent treatment with DTG plus either TDF and FTC (32%) or TAF and
FTC (68%), and they could have documented/suspected NRTI resistance. Participants
were randomised to switch to co-formulated BIC, TAF, and FTC or DTG plus TAF and FTC.
There were no changes in lipid plasma levels at week 48 in any arm. At baseline, 21% of
participants in each group underwent lipid-lowering therapy, 5% in the BIC and 3% in the
DTG arm started during the study (p = 0.52) (Table 5) [42].
In summary these studies demonstrated similar and neutral lipid profiles for DTG
and BIC, whereas BIC was superior to EVG/c only for TG.
3.5. Studies Comparing Triple Therapy and Dual Therapy That Include an INSTI in Naïve and in
Virologically Suppressed HIV-Infected Patients
In recent years, with the aim of reducing long-term toxicity, potential drug interactions,
and the pill burden, regimens comprising two antiretroviral drugs (dual therapy) have
been evaluated in naïve and virologically suppressed scenarios.
In the GEMINI 1 and 2 trials, naïve participants were randomised to receive a dual
therapy with DTG plus 3TC or a triple therapy with DTG, TDF, and FTC. At week 48,
TC, LDL-c, and TG increased in the two-drug regimen arm (adjusted mean changes: 12.4,
6.6, and 2.6, respectively) and decreased in the three-drug regimen arm (−5.8, −5.4, and
−7.1, respectively), with the differences between groups being significant for each variable
(p < 0.0001 for TC and LDL-c, p = 0.0457 for TG). A significantly greater increase was
observed in HDL-c in the dual regimen than in the triple regimen group (5.8 vs. 0.8;
p < 0.0001). A greater decrease in the TC/HDL-c ratio was observed in the triple regimen
group (−0.24 vs. −0.12; p = 0.0182) [43]. Mean changes at week 96 were similar to those
reported at week 48 (p < 0.05 for all comparisons) [44].
In two RCTs that included virologically suppressed patients undergoing treatment
with 3- or 4-ART drugs, participants were randomised to continue the same regimen
or switch to a co-formulated, dual therapy DTG and 3TC [45,46]. In the TANGO trial,
participants were administered 3- or 4-ART drugs that included TAF and FTC (INSTI 78%
(EVG/c 65%), NNRTI 13%, boosted-PI 8%). At week 48, TC, LDL-c TC/HDL-c, and TG
decreased in the dual therapy arm compared with patients that continued on the 3- or 4-
drug regimen (all p < 0.001, except the TC/HDL-c ratio at p = 0.017) [45]. In the SIMPL’HIV
trial, the baseline regimen included an INSTI (64%), an NNRTI (27%), or a boosted-PI (6%)
plus 2 NtRTI. At week 48, in the dual therapy arm, there was a slight decrease in TC of
9.3 (24), LDL-c of 6.2 (22), and TG of 9.7 (81.4), but this decrease was also observed in the 3-
or 4-drug-based regimen (−5 (27) for TC, 0.4 (23), LDL-c, and −12.4 (69) for TG) without
significant differences between arms (p > 0.05) (Table 6) [46].
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n = 372; 39; 91.1%
Baseline 1 189.2 111.9 54 132.7 3.9
Week 48 2 2.3% 6% 1.7% 6% 0.5%
DTG, 3TC,
n = 369; 40; 93.2%
Baseline 1 193 111.9 54 141.6 3.9





n = 511; 43; 79%
Baseline 1 186.7 108.8 53.3 126.3 3.73
Week 48 1 187 107.5 54.7 125.8 3.65
DTG, rilpivirine,
n = 513; 43; 77%
Baseline 1 184.3 107.2 52.3 126.4 3.78
Week 48 1 186.1 109 54.1 118 3.67
In the tables, only studies with baseline data are presented. * p-value < 0.05 for comparisons between treatment arms. Superindex numbers
indicate the statistical parameters to express data: 1 Mean; 2 Percentage change from baseline on adjusted ratio (week 48 to baseline).
In the SWORD trial, participants on a stable regimen consisting of two NtRTIs
(TDF 70%) plus a third drug (NNRTI 54% (36% efavirenz)), INSTI (20%), or boosted
PI (26%) were randomised to continue the same regimen or switch to DTG plus rilpivirine.
At week 48, the switch to DTG and rilpivirine had no effect on plasma concentrations of
TC, LDL-c, HDL-c, TG, or the TC/HDL-c ratio (Table 6) [47].
In summary, a small increase in lipids was observed with DTG and 3TC in contrast
to the decrease observed with triple therapy due to the intrinsic lipid-lowering effect
of TDF [33]. In simplification strategies, including INSTI, a slight but favourable lipid
change in participants switching to DTG plus 3TC was observed. However, no change
in lipids was observed in the SWORD trial, despite the withdrawal of TDF in a high
percentage of participants that reinforced the neutral effect on serum lipids of the DTG
plus rilpivirine combination.
3.6. Assessment of Other Lipoprotein-Related Atherogenic Biomarkers
LDL-c is the main goal of lipid-lowering therapy for CV risk prevention. However, the
qualitative properties of LDL-c are known to add information in the assessment of CV risk.
LDL consists of multiple subclasses that differ in size, density, lipid, and apolipoprotein
composition, metabolic behaviour, and correlation with CV risk. The predominance of
small and dense LDL particles, the so-called LDL phenotype B, is reported in lipid disorders,
obesity, and type 2 diabetes, and is considered a relevant risk factor for atherogenesis and
coronary heart disease [48–50]. Oxidized lipoproteins, both LDLox and HDLox, have
atherogenic properties [51]. Three of the RCTs described previously reviewed atherogenic
biomarkers of lipoproteins. In the ACTG 5260s, a CV sub-study of ACTG A5257 [14], at
week 96, an increase in LDLox was observed in RAL and both PI/r arms, whereas LDL
particle numbers declined only in the RAL arm, and no changes were observed in LDL
particle size in any arm. HDLox decreased, and the HDL particle number increased in both
PI/r arms [52]. In the SPIRAL [36] and NEAT [40] studies, the LDL particle phenotype
improved (increase in LDL size and decrease in the percentage of subjects with LDL
phenotype B) at week 48 with the switch of PI/r to RAL and DTG, respectively [53,54].
4. Conclusions
In conclusion, RAL, DTG, and BIC show a superior lipid profile compared with
PI/r, EFV, and EVG/c, in studies conducted in naïve participants, and the three INSTIs
are associated with a clinically significant benefit in lipoproteins in switching strategies.
Although the decrease in switching studies is shown to be lower than that observed with
lipid-lowering therapy [55], it may be enough to preserve a healthy lipid profile in a high
J. Clin. Med. 2021, 10, 3456 13 of 16
proportion of patients and contribute to preventing and reducing the increased CV risk
observed in PLWH.
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